UNSPSC 51413105: Fasudil

This classification denotes a protein kinase inhibitor with the molecular formula C14H17N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q0CH43PGXS, chemically known as 5-(1,4-diazepan-1-sulfonyl)isoquinoline but generally known as fasudil, which bears US NIH Compound Identifier 3547. European Medicines Agency schedules Fasudil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07515MIG.

UNSPSC 51413105 Fasudil (Commodity) represents a narrow pharmaceutical product line — a vasodilator used in emergency and acute care settings — but the code shows minimal direct solicitation activity. State and local governments procure this medication alongside broader advanced life support drug portfolios rather than as a standalone line item. The recent opportunities block contains no solicitations specifically for Fasudil; instead, the code appears tagged to emergency medical services medication bundles, cooperative purchasing agreements for generic multi-source pharmaceuticals, and state pharmacy benefit program initiatives that may include it as one component among many active pharmaceutical ingredients. Fire rescue departments, state health agencies, and cooperative purchasing alliances represent the issuing bodies most likely to encounter this code, though solicitations typically aggregate multiple medications under higher-level family or class codes rather than isolating a single commodity.

Activity supporting this code emerges from three jurisdictions. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications for Tampa Fire Rescue, with response due April 8, 2026, covering four specific medication line items (Labetalol, Epinephrine, Adenosine, and Diltiazem) but not naming Fasudil explicitly; the estimated contract value was $40,000 with a one-year term and options to renew. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities including Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. Fasudil procurement under this code remains infrequent; buyer interest concentrates on lower-cost commodity-aggregation vehicles rather than single-agent solicitations.